Optimizing implementation of long-acting, injectable Cabotegravir for HIV prevention among adolescents and young adults in Zambia

优化长效注射卡博特韦的实施，以预防赞比亚青少年和年轻人的艾滋病毒

基本信息

批准号：
10675014
负责人：
Laura Beres
金额：
$ 16.12万
依托单位：
JOHNS HOPKINS UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2022
资助国家：
美国
起止时间：
2022-08-01 至 2026-07-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10675014
关键词：
AIDS prevention Adherence Adolescent and Young Adult Affective Africa South of the Sahara Area Characteristics Clinical Trials Cognitive Collaborations Competence Contraceptive methods Country Data Data Collection Development Disease Educational Status Educational workshop Effectiveness Ensure Equity Exploration, Preparation, Implementation, and Sustainment Formulation Future Goals Guidelines HIV HIV Infections HIV risk Health Health Personnel Health care facility Health system Heterogeneity Incidence Individual Infectious Diseases Research Injectable Institution International Internet Intervention Knowledge Low income Maps Measures Mentored Research Scientist Development Award Mentors Methods Oral Outcome Perception Policies Population Prevalence Prevention Process Productivity Protocols documentation Recommendation Regimen Reporting Research Research Personnel Resource-limited setting Risk Assessment Sampling Scientist Specific qualifier value Stratification Subgroup Technology Testing Time Training Woman Zambia aged career career development cis-female cis-male evidence base experience experimental study health care delivery high risk high risk population implementation evaluation implementation facilitation implementation science implementation strategy improved innovation men novel outcome disparities population based pre-exposure prophylaxis preference prevent preventive intervention programs recruit research and development skills success transgender women uptake

项目摘要

This K01 Mentored Research Scientist Development Award application will facilitate Dr. Laura Beres’ career development as a leading, productive, independent researcher conducting innovative implementation science to maximize the real-world impact of HIV prevention interventions among high-risk populations in low-resource settings. The proposed training plan and research implementation in Zambia will allow Dr. Beres to meet her training objectives, developing the critical knowledge, skills, and competencies required to transition into an independent researcher. She will: 1. Gain expertise in pre-exposure prophylaxis (PrEP) and prevention interventions, 2. Develop skills in evidence-based, stakeholder-informed implementation strategy specification to optimize population-level impact of novel interventions, 3. Develop statistical expertise in discrete choice experiments and latent class analysis, 4. Establish capacity in internet-based recruitment and data collection in a low-resource setting, 5. Understand and measure developmental differences, including cognitive and affective development, among adolescents and young adults and their associations with HIV prevention. Dr. Beres’ mentoring team will support her successful achievement of her training, research, and career development goals. Dr. Chris Beyrer, her primary mentor, is an international expert in HIV prevention. She has five co-mentors: Dr. Sinead Delany-Moretlwe, an expert in LAI CAB as protocol chair of HPTN 084; Dr. Sheree Schwartz, a leading HIV implementation scientist with latent class analysis expertise; Dr. John F.P. Bridges, an international expert in discrete choice experiments; Dr. Julie Denison, an expert in adolescent and young adult development and HIV in Zambia; and Dr. Izukanji Sikazwe, a leading HIV researcher and Chief Executive Officer of Dr. Beres’ collaborating institution, the Centre for Infectious Disease Research in Zambia (CIDRZ). Her Scientific Advisor Dr. Smisha Agarwal is an expert in internet-based research in low-income settings. LAI CAB PrEP was found superior to daily oral PrEP in clinical trials and received US FDA approval in December 2021 with international regulatory approvals pending. LAI CAB PrEP has the potential to prevent HIV among those who experience barriers to effective oral PrEP use, including adolescents and young adults (AYA) in sub-Saharan Africa who remain at highest risk of HIV incidence. The proposed K01 research utilizes implementation science to establish evidence needed to optimize LAI CAB PrEP implementation for AYA in Zambia, minimizing the time from proven LAI CAB PrEP efficacy to population impact: Aim 1. Assess the fidelity and sustainability of implementation strategies for two related interventions: oral PrEP and injectable contraception, to inform LAI CAB implementation using participatory process mapping; Aim 2. Identify preferences for LAI CAB implementation and heterogeneity among AYA and healthcare workers using discrete choice experiments and latent class analysis with internet-based recruitment; Aim 3. Specify LAI CAB implementation strategies to support LAI CAB use and persistence. A future R01 will evaluate implementation.

这项K01指导研究科学家发展奖的应用程序将有助于劳拉·贝雷斯博士的职业发展是一名领先的，富有成效的独立研究人员，进行创新实施科学为了最大程度地利用低资源中的高风险人群中艾滋病毒预防干预措施的现实影响设置。拟议的培训计划和赞比亚的研究实施将使Beres博士能够与她见面培训目标，发展过渡到一个批判知识，技能和能力独立研究员。她将：1。获得暴露前预防（PREP）和预防方面的专业知识干预措施，2。发展基于证据的，基于利益相关者的实施策略规范的技能为了优化新颖干预措施的人群级别的影响，3。开发离散选择方面的统计专业知识实验和潜在类别分析，4。在基于Internet的招聘和数据收集中确定能力低资源环境，5。了解和衡量发展差异，包括认知和情感发展，青少年和年轻人及其与艾滋病毒预防的关联。博士 Beres的心理团队将支持她在培训，研究和职业上的成功成就发展目标。她的主要心理克里斯·贝勒（Chris Beyrer）博士是预防艾滋病毒的国际专家。她有五位联合官员：Sinead Delany-Moretlwe博士，LAI CAB的专家，担任HPTN 084的协议主席； Sheree博士 Schwartz，领先的HIV实施科学家，具有潜在的班级分析专业知识； John F.P.博士桥梁，一个国际离散选择实验专家；朱莉·丹尼森（Julie Denison）博士，青少年和年轻人的专家赞比亚的发展和艾滋病毒；艾滋病毒研究员兼首席执行官Izukanji Sikazwe博士赞比亚传染病研究中心Beres合作机构（CIDRZ）的官员。她的科学顾问Smisha Agarwal博士是低收入环境中基于互联网的研究专家。莱在临床试验中发现CAB Prep优于每日口服准备，并在12月获得了我们的FDA批准 2021年国际监管部门批准待定。 Lai Cab Prep有可能防止艾滋病毒那些遇到有效口服准备障碍的人，包括青少年和年轻人（aya）撒哈拉以南非洲仍处于艾滋病毒事件的最高风险。拟议的K01研究利用实施科学以建立优化AYA的LAI CAB PREP实施所需的证据赞比亚，最大程度地减少了从验证的LAI CAB PREP效率到人口影响的时间：AIM 1。评估实施策略的忠诚度和可持续性针对两种相关干预措施：口服准备和注射措施避孕，以使用参与过程映射告知LAI CAB实施；目标2。确定使用离散的AYA和医疗保健工人中LAI CAB实施和异质性的偏好通过基于Internet的招聘选择实验和潜在类别分析；目标3。指定LAI CAB 实施策略以支持LAI CAB使用和持久性。未来的R01将评估实施。